HER-2阳性乳腺癌分层治疗新策略

冀辰辰; 李健斌; 江泽飞

doi:10.12354/j.issn.1000-8179.2022.20211799

HER-2阳性乳腺癌分层治疗新策略

doi: 10.12354/j.issn.1000-8179.2022.20211799

中国人民解放军总医院第五医学中心肿瘤医学部（北京市100071）

基金项目: 本文课题受北京市科技计划课题项目（编号：Z181100001718215）资助

详细信息

作者简介:
冀辰辰：专业方向为乳腺癌的临床治疗及基础研究

通讯作者:
江泽飞 jiangzefei@csco.org.cn

计量
- 文章访问数: 345
- HTML全文浏览量: 128
- PDF下载量: 106
- 被引次数: 0
出版历程
- 收稿日期: 2021-11-30
- 录用日期: 2022-02-25
- 网络出版日期: 2022-03-10

New strategy for stratified treatment of HER-2-positive breast cancer

Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China

Funds: This work was supported by Beijing Science and Technology Project (No. Z181100001718215)

More Information

Corresponding author: Zefei Jiang; E-mail: jiangzefei@csco.org.cn

摘要

摘要: 人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）阳性乳腺癌恶性程度高，预后不良，抗HER-2靶向药物的出现改变了HER-2阳性乳腺癌患者的预后。然而，靶向药物的疗效会受不同治疗阶段的影响，早期阶段治疗策略会影响晚期阶段的治疗选择。既往根据治疗线数来决定用药方案，无法体现靶向药物的分层治疗理念。目前，根据患者既往用药情况，基于循证医学证据，结合指南与临床经验，现已形成抗HER-2靶向治疗的分层治疗模式。本文将就HER-2阳性乳腺癌不同阶段靶向治疗的分层策略进行综述。
- 乳腺癌 /
- HER-2阳性 /
- 靶向治疗
Abstract: Human epidermal growth factor receptor-2 (HER-2)-positive breast cancer is highly malignant and has poor prognosis. The emergence of anti-HER-2 targeted drugs has altered clinical outcomes of patients with HER-2-positive breast cancer. However, the efficacy of these drugs is affected by treatment at different disease stages. The treatment strategy at an early disease stage will affect treatment selection at a late disease stage. In the past, the drug regimen was determined according to different treatment lines, which could not reflect the stratified therapy concept of targeted drugs. Currently, a stratified treatment model for anti-HER-2 therapy has been established based on previous medication of patients and evidence-based medicine combined with guidelines and clinical experience. This study aimed to review stratified strategies for HER-2-positive breast cancer at different stages.
- breast cancer /
- HER-2 positive /
- targeted therapy

HTML全文

参考文献(25)

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. doi: 10.3322/caac.21654
[2]	Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J]. Science, 1987, 235(4785):177-182. doi: 10.1126/science.3798106
[3]	中国临床肿瘤学会指南工作委员会组织.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2021[M].北京:人民卫生出版社,2021.
[4]	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. Herceptin adjuvant (HERA) trial study team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA)trial[J]. Lancet, 2017, 389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2
[5]	Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up[J]. J Clin Oncol, 2021, 39(13):1448-1457. doi: 10.1200/JCO.20.01204
[6]	Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial[J]. Clin Breast Cancer, 2021, 21(1):80-91. doi: 10.1016/j.clbc.2020.09.014
[7]	Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31[J]. J Clin Oncol, 2011, 29(25):3366-3373. doi: 10.1200/JCO.2011.35.0868
[8]	Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14):1273-1283. doi: 10.1056/NEJMoa0910383
[9]	Tolaney SM, Guo H, Pernas S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2019, 37(22):1868-1875. doi: 10.1200/JCO.19.00066
[10]	Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)[J]. Ann Oncol, 2013, 24(9):2278-2284. doi: 10.1093/annonc/mdt182
[11]	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7
[12]	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study[J]. J Clin Oncol, 2019, 37(25):2206-2216. doi: 10.1200/JCO.19.00882
[13]	Von MinckwitzG, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7):617-628. doi: 10.1056/NEJMoa1814017
[14]	Mittendorf EA, Vila J, Tucker SL, et al. The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy: incorporation of prognostic biologic factors into staging after treatment[J]. JAMA Oncol, 2016, 2(7):929-936. doi: 10.1001/jamaoncol.2015.6478
[15]	Li JB, JiangZF. CSCO BC guideline: updates for HER2 positive breast cancer in 2020[J]. Transl Breast Cancer Res, 2020, 1:4. doi: 10.21037/tbcr.2020.03.05
[16]	Li JB, WangSS, Wang YS, et al. Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: a real-world study from China[J]. Oncologist, 2017, 22(11):1333-1338. doi: 10.1634/theoncologist.2017-0088
[17]	Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792.
[18]	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19):4265-4274. doi: 10.1200/JCO.2005.04.173
[19]	Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372(8):724-734. doi: 10.1056/NEJMoa1413513
[20]	Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
[21]	Yan M, Bian L, Hu XC, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13. doi: 10.21037/tbcr-20-25
[22]	Xu BH, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3):351-360. doi: 10.1016/S1470-2045(20)30702-6
[23]	Li F, Xu FR, Li JB, et al. Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study[J]. Ann Transl Med, 2021, 9(2):103. doi: 10.21037/atm-20-4054
[24]	中国临床肿瘤学会乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版)[J].中华医学杂志,2021,101(17):1226-1231. doi: 10.3760/cma.j.cn112137-20210318-00679
[25]	Modi SN, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med, 2020, 382(7):610-621. doi: 10.1056/NEJMoa1914510